DURAGRAFT VASCULAR CONDUIT SOLUTION
Purpose-built for the intraoperative window.
Intraoperative flushing and storage for saphenous vein grafts, from harvesting through grafting — at room temperature, for up to 4 hours.
INDICATION FOR USE
DuraGraft Vascular Conduit Solution is indicated for adult patients undergoing Coronary Artery Bypass Grafting surgeries and is intended for flushing and storage of the saphenous vein grafts from harvesting through grafting for up to 4 hours. DuraGraft is intended to maintain cell viability and structural integrity of vascular grafts during short-term storage at room temperature during the surgical procedure.
HOW DURAGRAFT WORKS
A physiologically balanced environment for a graft that has none.
From the moment the saphenous vein is harvested, it is without perfusion. Endothelial cell injury during harvesting and intraoperative storage contributes to oxidative damage. Saline and blood were never formulated to hold a graft in that state.
DuraGraft is a physiologically balanced, isotonic solution that maintains pH, osmolality, and ionic balance — supporting the structural integrity and cell viability of saphenous vein grafts from harvest through anastomosis.
pH BALANCE
Physiological
pH 7.4
OSMOLALITY
305 mOsm/kg
ANTIOXIDANTS
L-Glutathione
L-Ascorbic acid
NITRIC OXIDE PATHWAY
L-Arginine
Specific salts and organic components — normal constituents of blood — create a non-oxidizing, pH-balanced environment during the ischemic period.
SEAMLESS INTEGRATION
No protocol changes required.
DuraGraft is a two-component kit mixed at the point of use. It replaces the flushing and storage solution already in your workflow and covers the entire intraoperative window. No new equipment. No complex mixing. No added steps for your OR team.
Preparation
Simple two-component mix at point of use
Storage
Up to 4 hours at room temperature
Single Use
Intraoperative flush and storage
Evidence behind the solution.
Randomized trial
Within-patient comparison, 7 centers, MDCT at 12 months
2,964 patients
European DuraGraft Registry — 45 centers, 8 countries
DEN230002
FDA De Novo review — preclinical viability and morphology
FREQUENTLY ASKED QUESTIONS
Clinical
Neither saline nor autologous blood is FDA-indicated, quality-controlled, or specifically formulated for vein graft flushing and storage. DuraGraft is purpose-built and validated for this exact use.
Endothelial injury during the intraoperative window is linked to intimal hyperplasia and reduced long-term patency. DuraGraft is formulated to protect the endothelium during this window.
Regulatory & access
DuraGraft holds FDA De Novo classification (Class II) for the flushing and storage of saphenous vein grafts during CABG.
DuraGraft has been evaluated in randomized trials and a 2,904-patient registry with a well-characterized safety profile. See our Clinical Evidence page for details.
Reach out to our team to discuss adoption, value analysis committee materials, and kit ordering.